Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combination Therapy Using Mycophenylate Mofetil (CellCept) and Human Interferon beta1a (Rebif) in Early Treatment of Multiple Sclerosis

Next Previous
Trial Profile

Combination Therapy Using Mycophenylate Mofetil (CellCept) and Human Interferon beta1a (Rebif) in Early Treatment of Multiple Sclerosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon beta-1a (Primary) ; Mycophenolate mofetil
  • Indications Multiple sclerosis
  • Focus Biomarker; Pharmacodynamics

Most Recent Events

  • 23 Mar 2013 Results with focus on efficacy and tolerability presented at the 65th Annual Meeting of the American Academy of Neurology.
  • 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 17 Oct 2011 Planned End Date changed from 1 Dec 2010 to 1 May 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top